Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zentera Therapeutics
Shanghai, Shanghai Municipality, Chinazenteratherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Zentera has advanced multiple oncology candidates into early and mid-stage clinical trials in China. Its lead programs include a WEE1 inhibitor in Phase 1/2 for solid tumors, an oral SERD in Phase 1/2 for ER+/HER2– breast cancer, and a BCL‑2 inhibitor in Phase 1/2 for hematologic malignancies. The company has raised significant venture funding and aims to address unmet needs in both solid and liquid tumors.
- Therapeutic areas
- OncologyRare DiseasesHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
Collaboration with Pfizer on combination studies via the parent/licensor's global programfounding investors include OrbiMed Advisors Asia and Tybourne Capital Management
Beyond the preview
Go deeper on Zentera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zentera Therapeutics.